A clinical trial to assess the effectiveness of a combination immunotherapy versus active surveillance for treated hepatocellular patients who are at high risk of recurrence.
About this study
The purpose of this study is to compare the effects, good or bad, of combination immunotherapy (atezolizumab plus bevacizumab) versus observation (not receiving any treatment) on participants with completely resected or ablated hepatocellular cancer (HCC) who are at high risk for disease recurrence.
In this study, patients will receive either atezolizumab plus bevacizumab or no treatment.
Anticipated enrolment close date: 31 December 2022
Who can take part
Inclusion criteria
- First diagnosis of HCC who have undergone a curative resection/ablation (RFA or MWA only)
- High risk of HCC recurrence after resection/ablation
Exclusion criteria
- Prior or recurrent history of HCC
- Have received other treatment for HCC before surgery/ablation
- Known fibrolamellar HCC, sarcomatoid HCC or mixed cholangiocarcinoma and HCC
What's involved
Weekly immunotherapy infusions over three weeks
Ethics
All research in Australia involving human participants is reviewed by an independent group called a Human Research Ethics Committee (HREC). The ethical aspects of this research study have been approved by the Royal Melbourne Hospital HREC.
This study is being carried out according to the National Statement on Ethical Conduct in Human Research (2007). This statement protects the interests of people who agree to participate in human research studies.
The Clinical Trials Centre (CTC) is a dedicated, purpose-built space where we conduct clinical trials.
The CTC is located on Level 2 South. When you arrive, if you are unsure where to go, talk to one of our friendly volunteers or the information desk staff.